Sanofi (NASDAQ:SNY) Stake Reduced by Global Trust Asset Management LLC

Global Trust Asset Management LLC decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 10.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,771 shares of the company’s stock after selling 328 shares during the period. Global Trust Asset Management LLC’s holdings in Sanofi were worth $160,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Pinnacle West Asset Management Inc. acquired a new position in shares of Sanofi in the 3rd quarter worth $236,000. Brighton Jones LLC acquired a new position in shares of Sanofi in the 3rd quarter valued at $205,000. International Assets Investment Management LLC purchased a new position in Sanofi in the 3rd quarter worth about $7,038,000. Greenleaf Trust raised its holdings in Sanofi by 8.0% during the 3rd quarter. Greenleaf Trust now owns 13,814 shares of the company’s stock worth $796,000 after buying an additional 1,025 shares during the period. Finally, Private Advisor Group LLC lifted its stake in Sanofi by 2.6% during the third quarter. Private Advisor Group LLC now owns 52,338 shares of the company’s stock valued at $3,016,000 after buying an additional 1,339 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Up 4.4 %

Sanofi stock opened at $54.34 on Friday. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $137.89 billion, a PE ratio of 29.53, a P/E/G ratio of 1.40 and a beta of 0.60. The firm’s 50 day moving average price is $56.08 and its two-hundred day moving average price is $51.72.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.95 earnings per share. On average, research analysts predict that Sanofi will post 4.23 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SNY. StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Finally, Argus raised their target price on Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.